Summary | Hedge-fund manager Kyle Bass, who made a killing off
the housing market crash a few years back, is trying a new
strategy to make money, the WSJ reports: filing and publicizing
patent challenges against drug companies while also betting
against their shares. His latest target: Jazz Pharmaceuticals
and its narcolepsy drug Zyrem. ...
blogs.wsj.com | 08 April 2015